Cabotegravir and Rilpivirine As 2-Drug Oral Maintenance Therapy: LATTE W96 Results
Background: Cabotegravir (CAB, GSK744) is an HIV INSTI under development as both an oral and long-acting (LA) injectable. LATTE was designed to select an oral dose of CAB and to evaluate a two-drug ART regimen with rilpivirine (RPV), as suppressive maintenance therapy. Methods: Phase 2b, multicentre, partially-blinded, dose-ranging study in ART-naïve HIV infected adults, randomized…